# Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

> **NCT07081763** · PHASE2 · NOT_YET_RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 191 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Baricitinib 2 MG
- **DRUG:** Sirolimus 2 MG
- **OTHER:** Placebo of baricitinib 2 MG
- **OTHER:** Placebo of sirolimus 2 MG

## Key facts

- **NCT ID:** NCT07081763
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-05
- **Final completion:** 2030-11
- **Target enrollment:** 191 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07081763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07081763, "Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07081763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*